Qatar Healthcare Market Report 2026: Pharmaceutical Intelligence, HMC Access, and HTA Landscape

The Qatar healthcare market is estimated at USD 8.5–10 billion in 2026, projected to reach USD 14–16 billion by 2030. Qatar allocates approximately 4% of GDP to healthcare — relatively modest by GCC standards, but healthcare spending per capita is among the highest globally at approximately USD 4,500+ due to Qatar's high-income population. The market is government-dominated at roughly 80% of spend, with Hamad Medical Corporation as the primary system operator.

The Qatar pharmaceutical market is estimated at USD 900M–1.05 billion in 2026, growing at approximately 6.5% CAGR through 2030. HMC's pharmacy network — including the largest hospital pharmacy in the Middle East at Hamad General — controls formulary access for the majority of government pharmaceutical spend. Qatar imports approximately 98% of pharmaceutical requirements. Specialty pharmaceuticals in oncology, rare diseases, and biologics represent the highest-value growth segments.

Qatar is piloting a formal health technology assessment framework through the Supreme Council of Health, modelled on NICE in the UK and HAS in France. While not yet a mandatory submission requirement, HTA dossiers are increasingly expected for high-cost pharmaceuticals — particularly oncology biologics, rare disease therapies, and advanced therapies — before HMC formulary listing. BioNixus tracks Qatar HTA development, evidence expectations, and formulary committee decision criteria through MOPH and HMC primary research.

Qatar's FIFA World Cup 2022 legacy includes USD 2+ billion in healthcare infrastructure investment, including expanded emergency capacity, new specialty hospitals, and upgraded primary care centers. Post-event, Qatar is leveraging this infrastructure for medical tourism development — targeting the GCC's medical travel market. The healthcare workforce has expanded significantly, supporting higher procedural volumes and pharmaceutical consumption levels that persist as structural demand.

The Qatar pharmaceutical market is served by all major multinationals (Pfizer, Novartis, AstraZeneca, Roche, Sanofi, GSK, MSD) through local distribution partnerships. Regional companies including Julphar (UAE) and SPIMACO (Saudi Arabia) have presence in generic categories. Local manufacturing is minimal — Qatar National Pharmaceutical Company (Qatarpharm) is the primary domestic producer. HMC tender outcomes largely determine brand market share in the government channel.

BioNixus conducts Qatar pharmaceutical market research through quantitative HCP surveys (oncologists, endocrinologists, cardiologists, rheumatologists), HMC formulary committee research, MOPH registration tracking, and hospital consumption intelligence across HMC hospitals, Sidra Medicine, and private facilities. Our Qatar research capability spans qualitative depth interviews with KOLs, payer advisory board support, and competitive intelligence programs that have served global pharmaceutical launch teams across oncology, diabetes, and immunology.